3 results
Approved WMORecruiting
To determine the safety, feasibility, and tolerability of adding PIPAC with oxaliplatin (92 mg/m2) to systemic chemotherapy in patients with isolated PM from CRC.
Approved WMORecruiting
Improving the clinical effect and efficiency of DBS for PD by investigating patient specific patterns of neuronal cell activity in the brain that are associated with symptom-severity. This may improve the clinical effect of DBS, and also result in…
Approved WMORecruiting
This is a Phase 3 multicenter study that includes two periods. Period 1 is designed to compare the safety, tolerability, and efficacy of upadacitinib low dose once daily (QD) and high dose B QD versus placebo and versus adalimumab every other week (…